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Table 1. Demographic, radiochemical and clinical data for first episode psychosis patients and control subjects. 
Controls Patients chi-square t-value2 df Mann-whitney U value p-value
(N=16) (N=16)
Age 26.4 (8.4) 28.5 (8.4) 106.5 0.415
Gender Male/Female 7/9 11/5 2.032 1 0.154
Genotype HAB/MAB 9/7 8/8 0.125 1 0.723
Descriptive statistics BMI  21.9 (1.9) 22.9 (4.8) -0,722* 19.8 0.479
Education years 14.9 (2.2) 13.6 (3.3) 1.278 25 0.213
Nicotine-user Yes/No 0/16 2/14 NA3
PET measures Injected mass tracer (µg) 0.68 (0.57) 0.66 (0.32) 0.166 30 0.870
Specific radioactivity (GBq/µmol) 313.8 (213.4) 276.4 (170.8) 120.5 0.777
Injected radioactivity (MBq) 403.9 (52.5) 402.1 (69.5) 0.083 30 0.934
Duration of illness (months)1 7.9 (9.6)




Level of functioning1 CGI 4.6 (1.2)
(N=16) (N=15)
Cognitive measurements
MATRICS TMT 22.6 (4.6) 35.5 (14.4) 36 8.65*10-4
HVLT-R 28.4 (2.3) 21.2 (5.8) 26 1.65*10-4
WMS-III-SS 19.0 (2.2) 14.8 (3.4) 32.5 4.90*10-4
BVMT-R 29.0 (5.4) 19.1 (6.6) 4.581 29 8.10*10-5
Fluency 25.6 (6.7) 18.8 (4.2) 3.368 29 0.002
(N=14)
CPT-IP 2.9 (0.4) 2.0 (0.4) 5.316 28 1.20*10-5
(N=15) (N=13)
WCST PctErrors 14.6 (7.5) 33.3 (18.2) 27.5 0.00123
CatCompl 5.9 (0.3) 4.5 (2.1) 64 0.0315
Averages and standard deviations are reported as Mean (SD). PANSS=Positive and Negative Symptom Scale in Schizophrenia; CGI=Clinical Global Impression (1-6); WCST=Wisconsin 
Card Sorting Test; TMT=Trail Making Test: Part A; HVLT-R=Hopkins Verbal Learning Test - Revised; WMS-III-SS=Wechsler Memory Scale III: Spatial Span; BVMT-R=Brief Visuospatial 
Memory Test Revised; CPT-IP=Contiunous Performance Test-Identical Pairs; WCST=Wisconsin Card Sortin Test; PctErrors=Percent errors; CatCompl=Categories completed. *Equality of 
variance not assumed, Welch's Independent sample t-test was performed. 1. Ratings only exist for patient group 2. In the case of equality of variance Welch's t-test was performed. 3. 
Expected cell counts too low to perform a chi-square test.
Region Mean SD Mean SD t-value p-value
Whole Brain 1230.7 130.8 1256.0 126.2 -0.6 0.582
Grey Matter 738.7 61.7 739.1 71.8 -0.015 0.988
Frontal Cortex 153.7 12.3 156.1 18.5 -0.431 0.670
Temporal Cortex 110.5 7.5 111.8 13.1 -0.357 0.723
Hippocampus 8.8 0.8 8.7 0.7 0.255 0.801
SD=Standard deviation. All volumes expressed in cm3. p-value as determined using an 
independent sample t-test.  
Table 2. Comparison of measured ROI volumes between first episode patients with psychosis 
and healthy control subjects. 
Controls (N=16) Patients (N=16)
r df p-value
Duration of Illness (months)1 0.035 12 0.91
PANSS1 Positive 0.45 12 0.11
Negative 0.10 12 0.73
General 0.29 12 0.31
Total 0.35 12 0.22
Level of functioning1 CGI 0.41 12 0.14
Cognitive measures 2,3
MATRICS (N=15) TMT -0.41 10 0.19
HVLT_R 0.70 10 0.012
WMS_III_SS -0.082 10 0.80
BVMT_R 0.21 10 0.52
Fluency 0.016 10 0.96
(N=14) CPT_IP -0.15 9 0.66
WCST (N=13) PctErrors -0.049 8 0.89
CatCompl 0.016 8 0.97
r=partial correlation coefficient. 1. Controlling for TSPO genotype and gender. 2. Controlling 
for TSPO genotype, gender and age. 3. Bonferroni corrected alpha-value=0.00625.
Table 3. Partial correlations between GM VT and clinical and cognitive variables in patients 
with first episode psychosis.
